- UK-based Albumedix Ltd. is a leader in the field of
recombinant albumin-based solutions and a highly innovative and
profitable company
- Recombinant human albumin is a critical component in the
manufacture of innovative biopharmaceuticals, particularly for
modalities such as cell therapies, viral therapies and vaccines
- Sartorius will acquire all outstanding shares of Albumedix
Ltd. for approximately £415 million
GÖTTINGEN, Germany, Aug. 8, 2022
/PRNewswire/ -- The life science group Sartorius, through its
French listed subgroup Sartorius Stedim Biotech, has agreed to
acquire 100 percent of Albumedix Ltd. from private investors. The
Nottingham, UK-based company
provides best-in-class recombinant albumin-based solutions.
Recombinant human albumin is an important component for the
biopharmaceutical industry required for various applications, for
example as an animal-free additive to cell culture media and for
the stabilization of vaccines and viral therapies. The business,
founded in 1984, has more than 100 employees and is expected to
generate revenue of approximately £33 million in 2022 with a
significant double-digit EBITDA margin. The agreed purchase price
amounts to approximately £415 million. The
transaction is subject to regulatory approval and is expected to
close before the end of the third quarter of 2022.
"Albumedix will be an important addition to Sartorius' advanced
therapy solutions, particularly regarding our cell culture media
business, as it will enable us to strengthen our position as a
relevant supplier of innovative chemically defined media and
critical ancillary materials. This market offers high growth
potential due to the increasing regulatory requirements as well as
rising demand for the use of recombinant human albumin in
near-patient applications. Albumedix will also add important
formulation excipients to our vaccine production solutions,
allowing us to expand our existing customer relationships and forge
new ones," said René Fáber, member of the Executive Board for the
Bioprocess Solutions Division of Sartorius.
"We are delighted to be joining forces with Sartorius and look
forward to accelerating our ambitious growth plans in delivering
critical solutions to our global customers. We have been highly
impressed with Sartorius' knowledge and capabilities in the
bioprocessing markets, and we are excited to join this purposeful
journey. We believe Sartorius will bring tremendous value in
strengthening our market reach and broadening our innovation
capacity, as well as significantly scaling up our existing
platform. We remain focused on our promise of empowering excellence
in the life science industry," said Jonas S. Møller, CEO of
Albumedix.
Albumedix will be part of the Bioprocess Solutions Division, and
the existing 72,000-square-foot site in Nottingham will be established as a center of
excellence for innovation and GMP-compliant production of critical
raw materials.
Milbank LLP provided legal counsel to Sartorius in this
transaction. William Blair acted as
financial advisor to Albumedix, and Eversheds Sutherland provided
legal counsel.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2021, the company earned sales revenue of
some 3.45 billion euros. At the end
of 2021, nearly 14,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Logo -
https://mma.prnewswire.com/media/1696516/Sartorius_Logo.jpg
Contact Media Relations
Philipp
Grontzki
Head of External Communications
+49 (0)551.308.5581
philipp.grontzki@sartorius.com
Contact Investor Relations
Petra
Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-to-acquire-albumedix-strengthening-its-portfolio-of-innovative-advanced-therapy-solutions-301601642.html
SOURCE Sartorius AG
